Stock Events

Stock Events

Clearside Biomedical 

€0.000000
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-2,095.46%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.52MRevenue
-31.95MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLM.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
EyePoint
EYPT
Mkt Cap1.21B
EyePoint Pharmaceuticals focuses on developing treatments for eye diseases, directly competing with Clearside's ocular therapies.
Bausch Health Companies
BHC
Mkt Cap1.83B
Bausch Health Companies, through its eye health division, competes in developing treatments for various eye conditions.
Novartis
NVS
Mkt Cap305.1B
Novartis offers a broad portfolio of drugs, including treatments for eye diseases, competing on a global scale.
Regenxbio
RGNX
Mkt Cap686.54M
REGENXBIO's focus on AAV gene therapies for retinal diseases puts it in direct competition with Clearside's eye disease treatments.
Ocular Therapeutix
OCUL
Mkt Cap2.11B
Ocular Therapeutix develops innovative therapies for eye diseases, competing in the ocular drug delivery space.
GSK
GSK
Mkt Cap107.47B
GlaxoSmithKline, with its broad pharmaceutical portfolio, includes treatments for eye conditions, making it a competitor in the broader pharmaceutical market.

About

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Show more...
CEO
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Employees
32
Country
United States
ISIN
US1850631045

Listings

MU
DE
CLM0.MU
STU
DE
CLM0.STU
STU
DE
CLM.STU
OTC Link
US
CLSDQ

0 Comments

Share your thoughts

FAQ

What is Clearside Biomedical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Clearside Biomedical stocks are traded under the ticker CLM.STU.
What is Clearside Biomedical revenue for the last year?▼
Clearside Biomedical revenue for the last year amounts to 1.52M EUR.
What is Clearside Biomedical net income for the last year?▼
CLM.STU net income for the last year is -31.95M EUR.
How many employees does Clearside Biomedical have?▼
As of July 10, 2026, the company has 32 employees.
In which sector is Clearside Biomedical located?▼
Clearside Biomedical operates in the Health & Wellness sector.
When did Clearside Biomedical complete a stock split?▼
Clearside Biomedical has not had any recent stock splits.
Where is Clearside Biomedical headquartered?▼
Clearside Biomedical is headquartered in Alpharetta, United States.